AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of ...

AN2 Therapeutics (ANTX) has received extended funding from the Gates Foundation for its tuberculosis research collaboration with GSK (GSK), the drugmaker said Monday. The collaboration explores ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...

MENLO PARK, Calif.-- (BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

On Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive ...

Abstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies This press release contains forward-looking statements within the ...

AN2 Therapeutics (ANTX) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as ...

EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease ...

When AN2 Therapeutics set financial terms for the stock offering earlier this week, the company planned to offer 4 million shares in the range of $14 to $16 each. AN2 was able to boost the size of the ...

AN2 Therapeutics, Inc. announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research ...